Drug intelligence / Profile preview

GLK-40

Development stage: Preclinical
Lead developer: Glykos
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

GLK-40 is an antibody-drug conjugate (ADC) currently in the discovery phase of development by Glykos. It is being investigated for the treatment of various solid tumors. As an ADC, it is designed to utilize a monoclonal antibody to selectively deliver a cytotoxic payload to cancer cells, thereby minimizing systemic toxicity. The specific molecular target and the nature of the payload and linker technology used in GLK-40 have not been publicly disclosed by the sponsor.

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on GLK-40.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GLK-40.

Explore the full profile